Market Overview

Pharmaceutical Excipients Market To Reach USD 10.15 Billion By 2027

Share:

New York, April 01, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Pharmaceutical Excipients Market valued at USD 6.53 billion in 2019 and is expected to reach USD 10.15 billion by the year 2027, at a CAGR of 5.7%. Excipients are the products that do not show any activity of the drug but facilitates the drug delivery process. The increase in the outbreak of pandemic or epidemic diseases across the globe is the primary factor for boosting the growth of the market. The problems associated with instability, poor solubility, and absorption of active pharmaceutical ingredients are driving the demand for pharmaceutical excipients. The development of nanotechnology for the administration of drugs is further boosting the growth of the market. In 2015, the amount of manufacturing of final products of drugs in Japan accounted for 6,820.4 billion yen, the amount of import was 4,022 billion yen. Increasing outbreak of life threatening diseases and increasing incidences of resistance over traditional treatment plan resulting in increasing number of final production are expected to boost the market growth.

North America has obtained remarkable growth in the market due to the awareness among the consumers for better healthcare, government initiatives for research and development of new drugs, clinical trials, and due to better facilities for healthcare in the region. However, the high cost of drug development is the primary restraint to market growth.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/2713

The COVID-19 Impact: The sudden outbreak of COVID-19 has reported significant growth in the pharmaceutical excipients market. According to the recent epidemiological data the fight against COVID-19 is expected to continue furthermore for some considerable time, especially in Europe. Pharmaceutical companies are engaged in developing the appropriate and desired treatment plan or medicines. Increasing production of final products in the industry has gained huge demand of excipients required for the formulation. However, it might impact negatively to emerging nations in Asia such as China and India, due to the increased restrictions towards international trade i.e., export or import. In such circumstances, companies especially in US and Europe have shifted towards manufacturer from the same state or backward expansion strategies, i.e., companies are owning their own excipients manufacturing plants. For instance, ReForm Biologics, a pharmaceutical technology company and MilliporeSigma have entered an agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. Certain excipients have been established high acceptance for manufacturing drug for COVID-19 treatment for example, hydroxypropyl beta-cyclodextrins (HPβCD) it acts as functional excipient. Certain bodies are also playing vital role in market impact of COVID-19 outbreak. EXCiPACT updated position paper on COVID-19 (Coronavirus) EXCiPACT asbl is a non-profit organisation that require excipient users to qualify their suppliers based on GMP/GDP audits. It regulates such an independent, high quality, third party Certification Scheme available to pharmaceutical excipient manufacturers and distributors worldwide.

Further key findings from the report suggest

  • Evonik in the year 2017 had launched a new sterile, and ultra-low-metal content bioresorbable polymers known as RESOMER ZERO it is an ultra-low tin content PLGA poly (lactic-co-glycolic acid) excipient and is the first sterile controlled release (PLGA) excipient in the market. It was designed for the controlled-release parenteral drug formulation.
  • Croda International, in the year 2018 had launched Moonshine Effect Pigments, it is a range of borosilicate-based effect pigments, it is specially designed for personal care products, the quality borosilicate substrate produces the effect exceptional vibrancy, intensity, and color transmission for eye-catching results in cosmetic formulations.
  • JRS Pharma had received an EXCiPACT Certificate from DQS for the production of Microcrystalline Cellulose and Silicified Microcrystalline Cellulose and for Good Distribution Practice for the central logistic warehouse. The certificate justifies that the Micro cellulose is manufactured and distributed according to the EXCiPACT Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Certification Standard. The certificate is beneficial for the drug manufacturers to reduce their efforts and costs for performing quality control.
  • Oral formulations in the formulations segment have obtained the largest share due to the rise in demand for formulations like tablets, capsules, and oral solutions and suspensions. It is likely to grow with a CAGR of 5.9% in the forecast period.
  • Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), Croda International (UK). Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France) are the key players in the Pharmaceutical Excipients market

BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/2713

For this purpose, Reports and Data have segmented the Pharmaceutical Excipients market on the basis of products, functionality, formulations, end use, and region.

 Products Outlook (Revenue in Million USD; (2017–2027)

  • Organic Chemicals
    • Oleochemicals
      • Fatty Alcohols
      • Mineral Stearates
      • Glycerin
      • Other Oleochemicals
    • Carbohydrates
      • Sugars
        • Actual Sugars
          • Lactose
          • Sucrose
          • Dextrose (D-Glucose)
        • Sugar Alcohols
          • Mannitol
          • Sorbitol
          • Other Sugar Alcohols
        • Artificial Sweeteners
      • Cellulose
        • Microcrystalline Cellulose
        • Cellulose Ethers
        • CMC and Croscarmellose Sodium
        • Cellulose Esters
      • Starch
        • Modified Starch
        • Dried Starch
        • Converted Starch
      • Petrochemicals
        • Glycols
          • Polyethylene Glycol
          • Propylene Glycol
        • Povidones
        • Mineral Hydrocarbons
          • Petrolatum
          • Mineral Waxes
          • Mineral Oils
        • Acrylic Polymers
        • Other Petrochemicals
      • Proteins
      • Other Organic Chemicals
    • Inorganic Chemicals
      • Calcium Phosphate
      • Metal Oxides
      • Halites
      • Calcium Carbonate
      • Calcium Sulfate
      • Other Inorganic Chemicals
    • Others
      • Pharmaceutical-Grade Water 
      • Mucilage

Functionality Outlook (Revenue in Million USD; (2017–2027)

  • Fillers and Diluents
  • Suspending and Viscosity Agents
  • Coating Agents
  • Binders
  • Flavouring Agents and Sweeteners
  • Disintegrates
  • Colorants
  • Lubricants and Glidants
  • Preservatives
  • Emulsifying Agents
  • Others

Formulations Outlook (Revenue in Million USD; (2017–2027)

  • Oral Formulations
    • Tablets
    • Capsules
      • Hard Gelatin Capsules
      • Soft Gelatin Capsules
  • Liquid Formulations
  • Topical Formulations
  • Parenteral Formulations
  • Others

End Use Outlook (Revenue in Million USD; (2017–2027)

  • Pharmaceutical companies
  • Chemical companies
  • Others

Regional Outlook (Revenue in Million USD; (2017–2027)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America
    • Brazil

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/pharmaceutical-excipients-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Primary Logo

View Comments and Join the Discussion!
 

Latest Ratings

StockFirmActionPT
AFECanaccord GenuityDowngrades0.310
BAHRaymond JamesDowngrades
BXSPiper SandlerInitiates Coverage On23.0
CACIRaymond JamesDowngrades
HPMorgan StanleyDowngrades20.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com